MEMORIA 2022 - Área 1. Hematología y Oncología Clínico

Área 1. Hematología y Oncología Clínico - Experimental. Genética Clínica

OBJETIVOS CIENTÍFICOS VINCULADOS AL PLAN ESTRATÉGICO

Generar conocimiento científico de excelencia: tras conseguir los mejores resultados de la serie histórica del Área 1 en 2021, se ha conseguido mantener esos grandes resultados en 2022 tanto cuantitativamente como en en la calidad científica de nuestras publicaciones. Se han mejorado indicadores como el impacto medio, el porcentaje de primeros cuartiles. Aunque hemos bajado en liderazgo, las publicaciones lideradas son de mayor calidad.
Captación de talento científico: se han conseguido 4 ayudas de recursos humanos competitivas, destacando la concesión de una investigadora Ramón y Cajal. Además, gracias al aumento de la financiación se ha podido ampliar el personal de apoyo a la investigación que se tenía en 2021.
Dinamizar la captación de recursos: la captación de recursos ha disminuido con respecto a 2021 aunque se han conseguido 16 ayudas (3 más que en 2021) destacando la concesión de una ayuda europea. Los ingresos por estudios de investigación clínica a se han incrementado en más de un 42% con respecto a 2021.

7 Grupos de Investigación

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL (CONSOLIDADO)
CONTROL MOLECULAR DE LA PROLIFERACIÓN Y DIFERENCIACIÓN (CONSOLIDADO)
TERAPIAS MOLECULARES Y BIOMARCADORES DE TUMORES SÓLIDOS (CONSOLIDADO)
INTEGRACIÓN MORFOFUNCIONAL DE CÉLULAS Y TEJIDOS (CONSOLIDADO)
TROMBOEMBOLISMO VENOSO (CLÍNICO ASOCIADO)
METALOFÁRMACOS ANTITUMORALES NO CONVENCIONALES (CONSOLIDADO)
PATOLOGÍA MOLECULAR Y FARMACOGENÉTICA (CONSOLIDADO)

INDICADORES GENERALES

Nº Publicaciones

690.39

Impacto Total

7.67

Impacto Medio

Tipo	Nº Pubs	FI total	FI Medio
Originales	86 (95.56%)	626.11	7.28
Revisiones	4 (4.44%)	64.28	16.07

71.11

Q1%

18.89

D1%

FI >= 15

Tipo	Nº Q1	Nº D1	Nº FI >= 15
Originales	62	16	7
Revisiones	2	1	1

INDICADORES DE LIDERAZGO

41 (46.0%)

Nº Publicaciones

318.77

Impacto Total

7.77

Impacto Medio

	Nº Pubs	FI total	FI Medio
Mujer	20 (48.78%)	138.54	6.93
Hombre	21 (51.22%)	180.23	8.58

78.05

Q1%

19.51

D1%

FI >= 15

	Nº Q1	Nº D1	Nº FI >= 15
Mujer	16	3	2
Hombre	16	5	2

OTROS INDICADORES

20.25

HCP10% (2018-2022)

50.0

HCP10 Liderado% (2018-2022)

21.88

HCP10 Lid. Mujeres% (2018-2022)

1.5

Crown (2018-2022)

73.33

Open Access%

46.67

Col. International%

* Se muestran las 5 especies, los 10 genes y las 20 enfermedades más nombradas. Los valores están normalizados logarítmicamente en base al número de publicaciones.

INDICADORES EVOLUTIVOS

DESTACADAS

Jimenez-Fonseca P, Salazar R, Valenti V, ..., Carmona-Bayonas A*. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Annals of Oncology, 2022, 33, 786-793, PMID: 35462008, FI: 50.5

Marin-Quilez A, Di Buduo CA, Diaz-Ajenjo L, ..., Rivera J et al. Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis. Blood, 2022, blood.2022016995 [pii], PMID: 36395340, FI: 25.476

de la Morena-Barrio ME, Suchon P, Jacobsen EM, ..., Corral J*. Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood, 2022, 140, 140-151, PMID: 35486842, FI: 20.3

Drakeford C, Aguila S*, Roche F et al. von Willebrand factor links primary hemostasis to innate immunity. , 2022, 13, 6320, PMID: 36329021, FI: 17.694

Bravo-Perez C*, de la Morena-Barrio ME*, de la Morena-Barrio B, ..., Corral J*. Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia. American Journal of Hematology, 2022, 97, 216-225, PMID: 34800304, FI: 12.8

LISTADO COMPLETO

Farge D, Frere C, Connors JM et al. COLABORADORES: Ageno W, Ajauro F, Alcindor T, ..., Santos J et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, 2022, 23, e334-e347, PMID: 35772465, FI: 51.1

Bikdeli B, Caraballo C, Trujillo-Santos J et al. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. Jama Cardiology, 2022, 7, 857-865, PMID: 35830171, FI: 24.0

Chauvistre H, Shannan B, Daignault-Mill SM, ..., Rodriguez-Lopez JN et al. Persister state-directed transitioning and vulnerability in melanoma. , 2022, 13, 3055, PMID: 35650266, FI: 17.694

Tang LV, Tao Y, Feng Y, ..., Corral J et al. Gene editing of human iPSCs rescues thrombophilia in hereditary antithrombin deficiency in mice. Science Translational Medicine, 2022, 14, eabq3202, PMID: 36449603, FI: 17.1

Encinas C, Hernandez-Rivas JA, Oriol A, ..., de Arriba F et al. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68, PMID: 35440057, FI: 12.8

Guerrero C, Puig N, Cedena MT, ..., de Arriba F et al. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2598-2609, PMID: 35063966, FI: 11.5

Termini R, Zihala D, Terpos E, ..., De Arriba F et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clinical Cancer Research, 2022, CCR-22-1594 [pii], PMID: 36074126, FI: 11.5

Asleh K, Lluch A, Goytain A, ..., Ayala F et al. Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clinical Cancer Research, 2022, CCR-22-2191 [pii], PMID: 36346687, FI: 11.5

Marin-Quilez A, Vuelta E, Diaz-Ajenjo L, ..., Palma-Barqueros V et al. A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling. Journal of Thrombosis and Haemostasis, 2022, 10.1111/jth.15672 [doi], PMID: 35170221, FI: 10.4

Jaureguizar A, Jimenez D, Bikdeli B et al. COLABORADORES: Monreal M, Prandoni P, Brenner B, ..., Trujillo-Santos J et al. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2022, 161, 524-534, PMID: 34478718, FI: 9.6

Bravo-Perez C, Toderici M, Chambers JE, ..., de la Morena-Barrio ME*, Corral J. Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect. , 2022, 7, PMID: 36214221, FI: 9.484

Mateos MV, Hernandez MT, Salvador C, ..., de Arriba F et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European Journal of Cancer, 2022, 174, 243-250, PMID: 36067617, FI: 8.4

Castanon E, Sanchez-Arraez A, Jimenez-Fonseca P, ..., Carmona-Bayonas A*. Bayesian interpretation of immunotherapy trials with dynamic treatment effects. European Journal of Cancer, 2022, 161, 79-89, PMID: 34933154, FI: 8.4

Jimenez-Fonseca P, Gallardo E, Arranz Arija F, ..., Carmona-Bayonas A. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. European Journal of Internal Medicine, 2022, 100, 33-45, PMID: 35227541, FI: 8.0

Jimenez-Fonseca P, Salazar R, Valenti V, Carmona-Bayonas A et al. Learning in times of stress: Lessons from COVID-19 that will last throughout this century. European Journal of Internal Medicine, 2022, 96, 1-4, PMID: 34801401, FI: 8.0

Bastida JM, Malvestiti S, Boeckelmann D, Palma-Barqueros V et al. A Novel GATA1 Variant in the C-Terminal Zinc Finger Compared with the Platelet Phenotype of Patients with A Likely Pathogenic Variant in the N-Terminal Zinc Finger. , 2022, 11, PMID: 36291092, FI: 7.666

Palma-Barqueros V, Revilla N, Zaninetti C, ..., Lozano ML*. Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. Blood Advances, 2022, 6, 5244-5255, PMID: 35349645, FI: 7.5

Dalby A, Mezzano D, Rivera J et al. Introduction of an ancient founder glycoprotein VI (GP6) mutation into the Chilean population. Blood Advances, 2022, bloodadvances.2022008531 [pii], PMID: 35994634, FI: 7.5

Carreno-Tarragona G, Alvarez-Larran A, Harrison CN, ..., Ferrer-Marin F et al. CNL and aCML should be considered as single entity based on molecular profiles and outcomes. Blood Advances, 2022, bloodadvances.2022008204 [pii], PMID: 36375042, FI: 7.5

Martinez-Cuadron D, Megias-Vericat JE, Serrano J, ..., Amigo ML et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Advances, 2022, 6, 1278-1295, PMID: 34794172, FI: 7.5

Bonelli Joaquin, Ortega-Forte Enrique, Vigueras Gloria, ..., Ruiz Jose* et al. Polyurethane-polyurea hybrid nanocapsules as efficient delivery systems of anticancer Ir(III) metallodrugs Inorganic Chemistry Frontiers, 2022, 9, PMID: null, FI: 7.0

Plazas JG, Arias-Martinez A, Lecumberri A, ..., Carmona-Bayonas A*. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. , 2022, 7, 100514, PMID: 35714478, FI: 6.883

Vicente Conesa MA*, Zafra Poves M, Carmona-Bayonas A, ..., Ayala de la Pena F*. A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge. , 2022, 7, 100384, PMID: 35144121, FI: 6.883

Gonzalez P, Lozano P, Solano F. Unraveling the Metabolic Hallmarks for the Optimization of Protein Intake in Pre-Dialysis Chronic Kidney Disease Patients. , 2022, 14, PMID: 35334840, FI: 6.706

Lecumberri R, Ruiz-Artacho P, Tzoran I, ..., Trujillo-Santos J et al. Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. Thrombosis and Haemostasis, 2022, 122, 1594-1602, PMID: 35189661, FI: 6.7

Mora D, Nieto JA, Mateo J, ..., Trujillo-Santos J et al. Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy. Thrombosis and Haemostasis, 2022, 122, 570-577, PMID: 34107539, FI: 6.7

de la Morena-Barrio B, Stephens J, de la Morena-Barrio ME et al. Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency. Thrombosis and Haemostasis, 2022, 122, 1369-1378, PMID: 35764313, FI: 6.7

Carmona-Bayonas A, Verso M, Sanchez Canovas M et al. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial. Thrombosis and Haemostasis, 2022, 122, 1653-1661, PMID: 35381615, FI: 6.7

Ruiz-Artacho P, Lecumberri R, Trujillo-Santos J et al. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism. , 2022, 14, PMID: 36077663, FI: 6.575

Bravo-Perez C*, Carrillo-Tornel S, Garcia-Torralba E, Jerez A. Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness. , 2022, 14, PMID: 35267648, FI: 6.575

Navarro-Manzano E*, Luengo-Gil G*, Gonzalez-Conejero R, ..., Ayala de la Pena F*. Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer. , 2022, 14, PMID: 35625994, FI: 6.575

Asensi-Canto A*, Lopez-Abellan MD, Castillo-Guardiola V, ..., Luengo-Gil G*, Conesa-Zamora P*. Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment. , 2022, 14, PMID: 35805019, FI: 6.575

Zaragoza-Huesca D, Nieto-Olivares A, Garcia-Molina F, ..., Martinez-Martinez I*. Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. , 2022, 14, PMID: 35804878, FI: 6.575

Garcia-Fortes M, Hernandez-Boluda JC, Alvarez-Larran A, ..., Ferrer-Marin F et al. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. , 2022, 14, PMID: 35565461, FI: 6.575

Martinez-Cuadron D, Serrano J, Mariz J, ..., On Behalf Of The Pethema Group*. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia. , 2022, 14, PMID: 35681796, FI: 6.575

Gutierrez A, Bento L, Novelli S, ..., On Behalf Of The Grupo Espanol de Trasplante de Progenitores Hematopoyeticos Geth And Grupo Espanol de Linfoma Y Trasplante Autologo Geltamo*. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. , 2022, 14, PMID: 35681653, FI: 6.575

Puiggros A, Ramos-Campoy S, Kamaso J, ..., Garcia-Malo MD et al. Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). , 2022, 14, PMID: 35884436, FI: 6.575

Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, ..., Ferrer-Marin F et al. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. British Journal of Haematology, 2022, 10.1111/bjh.18440 [doi], PMID: 36089912, FI: 6.5

Carrillo-Tornel S*, Chen-Liang TH, Zurdo M, ..., Lopez AMH*, ..., Jerez A*. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition. British Journal of Haematology, 2022, 10.1111/bjh.18609 [doi], PMID: 36573331, FI: 6.5

Zaragoza-Huesca D, Martinez-Cortes C, Banegas-Luna AJ, ..., Martinez-Martinez I. Identification of Kukoamine A, Zeaxanthin, and Clexane as New Furin Inhibitors. , 2022, 23, PMID: 35269938, FI: 6.208

Bonelli J, Ortega-Forte E, Rovira A, ..., Ruiz J* et al. Improving Photodynamic Therapy Anticancer Activity of a Mitochondria-Targeted Coumarin Photosensitizer Using a Polyurethane-Polyurea Hybrid Nanocarrier. Biomacromolecules, 2022, 23, 2900-2913, PMID: 35695426, FI: 6.2

Alvarez-Larran A, Garrote M, Ferrer-Marin F et al. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 128, 2441-2448, PMID: 35417564, FI: 6.2

Gorog DA, Gue YX, Chao TF, ..., Roldan V et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, euac020 [pii], PMID: 35323922, FI: 6.1

de Alarcon R, Alburquerque-Gonzalez B, Fernandez-Valera A, ..., Luengo-Gil G*, Conesa-Zamora P*. Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2022, 37, 792-795, PMID: 34888693, FI: 6.1

Trujillo-Santos J*, Farge-Bancel D, Pedrajas JM et al. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. , 2022, 6, e12736, PMID: 35664535, FI: 5.953

Li F, Zhang H, Tao Y, ..., Carmona-Bayonas A et al. Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation. Therapeutic Advances in Neurological Disorders, 2022, 15, 17562864221104508, PMID: 35755967, FI: 5.9

Luengo-Gil G*, Conesa-Zamora P*. Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. , 2022, 6, 2100051, PMID: 35284089, FI: 5.135

Markova L, Novohradsky V, Kasparkova J, Ruiz J et al. Dipyridophenazine iridium(III) complex as a phototoxic cancer stem cell selective, mitochondria targeting agent. Chemico-Biological Interactions, 2022, 360, 109955, PMID: 35447138, FI: 5.1

Estrada N, Zamora L, Ferrer-Marin F et al. Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients. , 2022, 11, PMID: 36294538, FI: 4.964

Garcia-Molina P, Garcia-Molina F, Teruel-Puche JA, Rodriguez-Lopez JN et al. The Relationship between the IC(50) Values and the Apparent Inhibition Constant in the Study of Inhibitors of Tyrosinase Diphenolase Activity Helps Confirm the Mechanism of Inhibition. , 2022, 27, PMID: 35630619, FI: 4.927

Zaragoza-Huesca D, Garrido-Rodriguez P, Jimenez-Fonseca P et al. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. , 2022, 10, PMID: 35052827, FI: 4.757

Lazaro-Sanchez AD, Juarez Marroqui A, Quesada Rico JA et al. Risk Factors for Cancer Mortality in Spain: Population-Based Cohort Study. , 2022, 19, PMID: 36011484, FI: 4.614

Martinez-Urbistondo D, de la Garza RG, Villares-Fernandez P et al. COLABORADORES: Adarraga MD, Aibar J, Alonso J, ..., Trujillo-Santos J et al. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Internal and Emergency Medicine, 2022, 17, 725-734, PMID: 34626318, FI: 4.6

Sanchez R, Dorado S, Ruiz-Heredia Y, ..., Ferrer-Marin F et al. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA. Scientific Reports, 2022, 12, 13057, PMID: 35906470, FI: 4.6

de la Morena-Barrio B, Orlando C, Sanchis-Juan A, ..., Corral J*. Molecular Dissection of Structural Variations Involved in Antithrombin Deficiency. Journal of Molecular Diagnostics, 2022, 24, 462-475, PMID: 35218943, FI: 4.1

Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A et al. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100, PMID: 33508849, FI: 4.1

Busto N, Vigueras G, Cutillas N, ..., Ruiz J*. Inert cationic iridium(III) complexes with phenanthroline-based ligands: application in antimicrobial inactivation of multidrug-resistant bacterial strains. Dalton Transactions, 2022, 51, 9653-9663, PMID: 35713595, FI: 4.0

Murgier M, Bertoletti L, Bikdeli B, ..., Trujillo-Santos J et al. Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. Journal of Thrombosis and Thrombolysis, 2022, 54, 58-66, PMID: 35072919, FI: 4.0

Ding WY, Rivera-Caravaca JM, Marin F et al. Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. Journal of Thrombosis and Thrombolysis, 2022, 54, 1-6, PMID: 35426602, FI: 4.0

Rodenas-Quinonero I, Chen-Liang T, Martin-Santos T, ..., Ortuno FJ*. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study. Cancer Medicine, 2022, 10.1002/cam4.5424 [doi], PMID: 36373169, FI: 4.0

Navarro Santana B, Garcia Torralba E, Verdu Soriano J et al. Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis. Journal of Gynecologic Oncology, 2022, 33, e21, PMID: 35245000, FI: 3.9

Paramo JA, Lozano ML, Gonzalez-Porras JR et al. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Medicina Clinica, 2022, 158, 82-89, PMID: 34311973, FI: 3.9

Gomez D, Carmona-Bayonas A, Hernandez R et al. Stoic attitude in patients with cancer from the NEOcoping study: Cross-sectional study. Plos one, 2022, 17, e0269712, PMID: 35901019, FI: 3.7

de la Morena-Barrio ME, Corral J, Lopez-Garcia C, ..., Canovas SJ*, de la Morena G. Contact pathway in surgical and transcatheter aortic valve replacement. Frontiers in Cardiovascular Medicine, 2022, 9, 887664, PMID: 35935621, FI: 3.6

Valcarcel S, Gallego J, Jimenez-Fonseca P, ..., Carmona-Bayonas A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. Journal of Cancer Research and Clinical Oncology, 2022, 10.1007/s00432-022-04294-6 [doi], PMID: 36042046, FI: 3.6

Roldan V*, Martinez-Montesinos L, Lopez-Galvez R, ..., Rivera-Caravaca JM*, Marin F. Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. , 2022, 12, PMID: 35330486, FI: 3.508

de Los Reyes-Garcia AM, Rivera-Caravaca JM, Zapata-Martinez L, ..., Martinez C*, Gonzalez-Conejero R*. MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction. , 2022, 12, PMID: 35887682, FI: 3.508

Triguero A, Pedraza A, Perez-Encinas M, ..., Ferrer-Marin F et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Annals of Hematology, 2022, 101, 2231-2239, PMID: 36042023, FI: 3.5

Vilorio-Marques L, Castanon Fernandez C, Mora E, ..., Chen-Liang T et al. Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. Therapeutic Advances in Hematology, 2022, 13, 20406207221127547, PMID: 36199837, FI: 3.4

Bishton M, Marshall S, Harchowal J, ..., Sanchez Blanco JJ et al. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe. Hematological Oncology, 2022, 40, 370-380, PMID: 35168291, FI: 3.3

Jimenez-Marco T, Castrillo A, Hierro-Riu F, ..., Rivera J*. Frozen and cold-stored platelets: reconsidered platelet products. Platelets, 2022, 33, 27-34, PMID: 34423718, FI: 3.3

Ferrer-Marin F*, Sola-Visner M. Neonatal platelet physiology and implications for transfusion. Platelets, 2022, 33, 14-22, PMID: 34392772, FI: 3.3

Abrisqueta M*, Cerdido S, Sanchez-Beltran J, ..., Jimenez-Cervantes C*. MGRN1 as a Phenotypic Determinant of Human Melanoma Cells and a Potential Biomarker. , 2022, 12, PMID: 35892921, FI: 3.251

Obispo-Portero B, Cruz-Castellanos P, Jimenez-Fonseca P, ..., Carmona-Bayonas A et al. Anxiety and depression in patients with advanced cancer during the COVID-19 pandemic. Supportive Care in Cancer, 2022, 30, 3363-3370, PMID: 34993652, FI: 3.1

Perez-Hernandez C, Canovas ML, Carmona-Bayonas A et al. A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study. Journal of Pain Research, 2022, 15, 2181-2196, PMID: 35942117, FI: 2.7

Tamariz-Amador LE, Rodriguez-Otero P, Jimenez-Ubieto A, ..., De Arriba F et al. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia, 2022, 22, e844-e852, PMID: 35688793, FI: 2.7

Triguero A, Xicoy B, Zamora L, ..., Chen TH et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. Leukemia Research, 2022, 116, 106836, PMID: 35405632, FI: 2.7

Cruz-Castellanos P, Gil-Raga M, Jimenez-Fonseca P, ..., Garcia-Torralba E et al. Uncertainty and hope in relation to anxiety and depression in advanced lung cancer. Bmj Supportive & Palliative Care, 2022, spcare-2022-003882 [pii], PMID: 36100428, FI: 2.7

Bizkarguenaga M, Gomez-Santos L, Madrid JF*, ..., Alonso E*. Zona Pellucida sperm-binding protein 3 receptor distribution during Gopc(-/-) globozoospermic spermatogenesis. Microscopy Research and Technique, 2022, 85, 1454-1464, PMID: 34870349, FI: 2.5

Velasco-Durantez V, Jimenez-Fonseca P, Martin Abreu CM, ..., Carmona-Bayonas A et al. Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic. Cancer Investigation, 2022, 40, 475-482, PMID: 35468046, FI: 2.4

Carmona-Bayonas A, Jimenez-Fonseca P, Gallego J et al. Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries. Cancer Investigation, 2022, 40, 1-13, PMID: 34709109, FI: 2.4

Valenti V, Jimenez-Fonseca P, Msaouel P, ..., Carmona-Bayonas A*. Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer Investigation, 2022, 40, 184-188, PMID: 34919008, FI: 2.4

Sancho JM, Marin-Niebla A, Fernandez S, ..., Perez-Ceballos E et al. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. International Journal of Hematology, 2022, 116, 381-392, PMID: 35551632, FI: 2.1

Sanchez-Villalobos JM*, Fortuna-Alcaraz ML, Serrano-Velasco L, ..., Perez-Vicente JA*. Breath-Hold Diving-Related Decompression Sickness with Brain Involvement: From Neuroimaging to Pathophysiology. Tomography, 2022, 8, 1172-1183, PMID: 35645382, FI: 1.9

Lozano ML*. New developments in the diagnosis of primary immune thrombocytopenia. Blood Coagulation & Fibrinolysis, 2022, 33, S5-S7, PMID: 34636811, FI: 1.1

AYUDAS CONCEDIDAS EN 2022

TOTAL DE AYUDAS CONCEDIDAS

Nº Ayudas

1.84M €

Financiación

TOTAL DE AYUDAS RECURSOS HUMANOS CONCEDIDAS

Nº Ayudas

0.58M €

Financiación

TOTAL DE AYUDAS PROYECTOS I+D+i CONCEDIDAS

Nº Ayudas Europeas

0.05M €

Financiación Europea

Nº Ayudas Nacionales

0.89M €

Financiación Nacional

Nº Ayudas Regionales

0.29M €

Financiación Regional

TOTAL DE REDES CONCEDIDAS

Nº Ayudas

0.0M €

Financiación

OTRAS AYUDAS COMPETITIVAS CONCEDIDAS (MOVILIDAD, ORGANIZACIÓN DE EVENTOS CIENTÍFICOS, ...)

Nº Ayudas

21.39K €

Financiación

PROYECTOS DE I+D+i Y AYUDAS DE RRHH ACTIVAS EN 2022

TOTAL AYUDAS

RECURSOS HUMANOS

REDES

PROYECTOS INTERNACIONALES

PROYECTOS NACIONALES

PROYECTOS REGIONALES

INICIADA EN 2022

Nº Estudios

Nº Ensayos Clínicos

Nº Producto Sanitario

Nº Estudios Post-Autorización

Nº Otros Estudios

ACTIVOS EN 2022

123

Nº Estudios

Nº Ensayos Clínicos

Nº Producto Sanitario

Nº Estudios Post-Autorización

Nº Otros Estudios

FACTURACIÓN EN 2022

0.56M €

Facturado

Nº Tesis (2 con mención internacional)